NXN-677
Preclinical- Indications
- Movement disorders
Company intelligence / Profile preview
NeurAxon Inc.
Mississauga/Toronto, Ontario, Canadaknighttx.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
NeurAxon Inc. was a Canadian biotech/pharmaceutical company focused on developing next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS). Its lead candidate, NXN‑188, combined nNOS inhibition with serotonin receptor agonism for the treatment of acute migraine. The company built a pipeline of first-in-class selective nNOS inhibitors aimed at addressing unmet needs in pain management and potentially other CNS-related conditions. As of the latest available information, NeurAxon had raised nearly $29 million from top-tier investors but has since exited and appears inactive.
- Therapeutic areas
- Rare DiseasesNeurology
- Modalities
- small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on NeurAxon Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeurAxon Inc..